WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/092326    International Application No.:    PCT/US2007/002926
Publication Date: 16.08.2007 International Filing Date: 01.02.2007
A61K 31/52 (2006.01), A61K 31/505 (2006.01), A61K 31/675 (2006.01), A61P 31/18 (2006.01)
Applicants: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION [US/US]; Technology Transfer Office, 4770 Buford Highway, MS K79, Atlanta, GA 30341 (US) (For All Designated States Except US).
HENEINE, Walid [US/US]; (US) (For US Only).
FOLKS, Thomas [US/US]; (US) (For US Only).
JANSSEN, Robert [US/US]; (US) (For US Only).
OTTEN, Ronald [US/US]; (US) (For US Only).
GARCIA-LERMA, J., Gerardo [ES/US]; (US) (For US Only)
Inventors: HENEINE, Walid; (US).
FOLKS, Thomas; (US).
JANSSEN, Robert; (US).
OTTEN, Ronald; (US).
GARCIA-LERMA, J., Gerardo; (US)
Agent: GOLDSTEIN, Avery, N.; Gifford, Krass, Sprinkle, Anderson & Citkowski, P., C., 2701 Troy Center Drive, Suite 330, Post Office Box 7021, Troy, MI 48007-7021 (US)
Priority Data:
60/764,811 03.02.2006 US
11/669,547 31.01.2007 US
Abstract: front page image
(EN)A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self- replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.
(FR)L'invention concerne un procédé visant à protéger un hôte primate contre une infection à autoréplication par un rétrovirus de l'immunodéficience. Pour ce faire, on administre à l'hôte primate une combinaison d'une dose pharmaceutiquement efficace d'un inhibiteur nucléosidique de la transcriptase inverse et d'une dose pharmaceutiquement efficace d'un inhibiteur nucléotidique de la transcriptase inverse, avant l'exposition au rétrovirus de l'immunodéficience. L'administration est efficace si elle est fournie par une dose unique dans les 24 heures avant l'exposition. Un régime de doses journalières régulières confère aussi efficacement une protection contre un rétrovirus de l'immunodéficience qui s'autoréplique après avoir infecté un hôte primate. Le procédé de lutte contre la transmission d'un rétrovirus dans une population consiste à administrer la combinaison décrite à une sous-population présentant un risque élevé de contracter une infection rétrovirale de l'immunodéficience, avant l'exposition sexuelle à une source de rétrovirus de l'immunodéficience, afin d'empêcher l'autoréplication dudit rétrovirus chez un membre de la sous-population.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)